Lightlake appoints VP, medical affairs
This article was originally published in Scrip
Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments using opioid antagonists, has named Arvind Agrawal executive vice-president of medical affairs. During his career, Mr Agrawal has overseen, managed, and delivered global Phase I-IV clinical studies and has experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, he was head of medical affairs for new products at Mundipharma.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.